NDA 217294 · Sq Innovation
Lasix Onyu
Furosemide · Subcutaneous · Loop Diuretic
Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Oct 7, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
345
66 Phase 3, 33 recruiting
FAERS reports
265,538
219,231 serious, 40,876 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 14, 2025.
Lasix ONYU is a loop diuretic indicated for the treatment of edema in adult patients with chronic heart failure. ( 1.1 ) 1.1 Congestion Lasix ONYU is indicated for the treatment of edema in adult patients with chronic heart failure. 1.1 Congestion Lasix ONYU is indicated for the treatment of edema in adult patients with chronic heart failure.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- LASIX ONYU · FUROSEMIDE 80MG/2.67ML (30MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Furosemide" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Platform of Randomized Adaptive Clinical Trials in Critical IllnessPivotal-lookingRecruiting
University Health Network, TorontoAcademic, hospital or other
NCT05440851 · 6,250 participants (planned) · Start Apr 30, 2023 · Primary completion Mar 31, 2027
Drug: Early Cohort corticosteroid dose; Extended Cohort corticosteroid dose and 6 more · For: Respiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
Sites: Tucson, Arizona; Los Angeles, California; San Diego, California · 103 sites in all
- Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationPivotal-lookingNot yet recruiting
Tibet Autonomous Region People's HospitalAcademic, hospital or other
NCT07639931 · 3,035 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 20, 2028
Drug: Multicenter study of HAPE group:NO Group · For: Severe High Altitude Pulmonary Edema; Severe High Altitude Cerebral Edema
Sites: Lhasa, China
- TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart FailurePivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03296813 · 2,973 participants · Start Jul 11, 2018 · Primary completion Jul 29, 2022
Drug: Torsemide; Furosemide · For: Heart Failure
Sites: Alexander City, Alabama; Huntsville, Alabama; Tucson, Arizona · 60 sites in all
- Effects of Fluid Balance Control in Critically Ill PatientsPivotal-lookingCompleted
Central Hospital, Nancy, FranceAcademic, hospital or other
NCT02765009 · 1,411 participants · Start Jun 1, 2016 · Primary completion Jul 31, 2019
Drug: diuretics; albumin · For: Fluid Shifts; Critical Care
Sites: Belfort, France; Dijon, France; Lyon, France · 11 sites in all
- Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS StudyPivotal-lookingCompleted
Heart Care FoundationAcademic, hospital or other
NCT00421863 · 1,111 participants · Start Feb 2005 · Primary completion Jan 2009
Drug: Triatec 10 mg; Triatec HCT 5 and 7 more · For: Hypertension
Sites: San Pietro Vernotico, Italy; Chiari, Italy; Trebisacce, Italy · 45 sites in all
- Acetazolamide or Metolazone in Acute Heart FailurePivotal-lookingNot yet recruiting
Clinica Alemana de SantiagoAcademic, hospital or other
NCT06273397 · 1,050 participants (planned) · Start May 1, 2024 · Primary completion Mar 1, 2027
Drug: Acetazolamide 250 MG; Metolazone 2.5 MG and 1 more · For: Heart Failure Acute; Decompensated Heart Failure
- DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart FailurePivotal-lookingRecruiting
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT05276219 · 1,041 participants (planned) · Start Sep 14, 2023 · Primary completion May 1, 2027
Drug: Furosemide Injection; Isosorbide Dinitrate and 1 more · For: Pulmonary Edema; Congestive Heart Failure; Acute Heart Failure
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea18,437
- acute kidney injury16,467
- fatigue13,248
- diarrhoea13,195
- death12,368
- nausea11,534
- fall11,003
- off label use10,842
- drug ineffective10,424
- hypotension10,330
- pneumonia10,172
- dizziness9,887
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,479 |
| 2005 | 3,857 |
| 2006 | 3,623 |
| 2007 | 3,214 |
| 2008 | 3,608 |
| 2009 | 3,997 |
| 2010 | 4,832 |
| 2011 | 6,479 |
| 2012 | 7,274 |
| 2013 | 7,405 |
| 2014 | 10,059 |
| 2015 | 13,254 |
| 2016 | 16,201 |
| 2017 | 16,716 |
| 2018 | 21,192 |
| 2019 | 23,004 |
| 2020 | 20,355 |
| 2021 | 18,734 |
| 2022 | 16,306 |
| 2023 | 16,473 |
| 2024 | 17,411 |
| 2025 | 16,227 |
| 2026 | 11,831 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Trullàs JC, Morales-Rull JL, Casado J, et al. · Eur Heart J 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Simultaneous Use of Hypertonic Saline and IV Furosemide for Fluid Overload: A Systematic Review and Meta-Analysis.
Liu C, Peng Z, Gao X, et al. · Crit Care Med 2021 · Meta-Analysis, Systematic Review
- Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: An updated systematic review and meta-analysis.
Lee TH, Kuo G, Chang CH, et al. · PLoS One 2021 · Comparative Study, Meta-Analysis
- Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials.
Cannatà A, Anastasia G, De Marzo V, et al. · Eur Heart J Cardiovasc Pharmacother 2026 · Systematic Review, Meta-Analysis
- Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials.
Ng KT, Yap JLL · Anaesthesia 2018 · Comparative Study, Meta-Analysis
- Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intrapatient Comparison of 3 Diuretic Regimens (DEA-HF).
Abbo AR, Gruber A, Volis I, et al. · JACC Heart Fail 2024 · Randomized Controlled Trial, Comparative Study
Sponsor: Sq Innovation
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.